Santhera Pharmaceuticals Holding AG 0QN1.L Stock
Santhera Pharmaceuticals Holding AG Price Chart
Santhera Pharmaceuticals Holding AG 0QN1.L Financial and Trading Overview
| Santhera Pharmaceuticals Holding AG stock price | 9.44 CHF |
| Previous Close | 0.92 CHF |
| Open | 0 CHF |
| Bid | 0 CHF x 0 |
| Ask | 0 CHF x 0 |
| Day's Range | 0 - 0 CHF |
| 52 Week Range | 0 - 1.4 CHF |
| Volume | 88.93K CHF |
| Avg. Volume | 7.76K CHF |
| Market Cap | 102.91K CHF |
| Beta (5Y Monthly) | 0.607662 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.625 CHF |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QN1.L Valuation Measures
| Enterprise Value | 99.96M CHF |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.01377131 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 13.376 |
| Enterprise Value/EBITDA | -2.349 |
Trading Information
Santhera Pharmaceuticals Holding AG Stock Price History
| Beta (5Y Monthly) | 0.607662 |
| 52-Week Change | -14.29% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.4 CHF |
| 52 Week Low | 0 CHF |
| 50-Day Moving Average | 0.72 CHF |
| 200-Day Moving Average | 0.79 CHF |
0QN1.L Share Statistics
| Avg. Volume (3 month) | 7.76K CHF |
| Avg. Daily Volume (10-Days) | 22.1K CHF |
| Shares Outstanding | 6.44M |
| Float | 47.89M |
| Short Ratio | N/A |
| % Held by Insiders | 10.44% |
| % Held by Institutions | 1.70% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -612.41% |
| Gross Margin | 51.93% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -36.94% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 7.47M CHF |
| Revenue Per Share (ttm) | 0.12 CHF |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -42559000 CHF |
| Net Income Avi to Common (ttm) | -71076000 CHF |
| Diluted EPS (ttm) | -1.625 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.35M CHF |
| Total Cash Per Share (mrq) | 0.02 CHF |
| Total Debt (mrq) | 44.44M CHF |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.062 |
| Book Value Per Share (mrq) | -0.663 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -29843000 CHF |
| Levered Free Cash Flow (ttm) | -24455876 CHF |
Profile of Santhera Pharmaceuticals Holding AG
| Country | United Kingdom |
| State | N/A |
| City | Pratteln |
| Address | Hohenrainstrasse 24 |
| ZIP | 4133 |
| Phone | 41 61 906 89 50 |
| Website | https://www.santhera.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 45 |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Q&A For Santhera Pharmaceuticals Holding AG Stock
What is a current 0QN1.L stock price?
Santhera Pharmaceuticals Holding AG 0QN1.L stock price today per share is 9.44 CHF.
How to purchase Santhera Pharmaceuticals Holding AG stock?
You can buy 0QN1.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Santhera Pharmaceuticals Holding AG?
The stock symbol or ticker of Santhera Pharmaceuticals Holding AG is 0QN1.L.
How many shares does Santhera Pharmaceuticals Holding AG have in circulation?
The max supply of Santhera Pharmaceuticals Holding AG shares is 113.81K.
What is Santhera Pharmaceuticals Holding AG Price to Earnings Ratio (PE Ratio)?
Santhera Pharmaceuticals Holding AG PE Ratio is now.
What was Santhera Pharmaceuticals Holding AG earnings per share over the trailing 12 months (TTM)?
Santhera Pharmaceuticals Holding AG EPS is -1.625 CHF over the trailing 12 months.